Nomogram to predict prostate cancer diagnosis on primary transrectal ultrasound-guided prostate biopsy in a contemporary series

Christopher J. Diblasio, Ithaar H. Derweesh, Michael M. Maddox, Reza Mehrazin, Changhong Yu, John B. Malcolm, Michael A. Aleman, Anthony Patterson, Robert Wake, Michael W. Kattan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Transrectal ultrasound-guided biopsy (TRUSB) remains the mainstay for prostate cancer (CaP) diagnosis. Numerous variables have shown associations with development of CaP. We present a nomogram that predicts the probability of detecting CaP on TRUSB. Methods: After obtaining institutional review board approval, all patients undergoing primary TRUSB for CaP detection at a single center at our institution between 2/2000 and 9/2007 were reviewed. Patients undergoing repeat biopsies were excluded, and only the first biopsy was included in the analysis. Variables included age at biopsy, race, clinical stage, prostate specific antigen (PSA), number of cores removed, TRUS prostate volume (TRUSPV), body mass index, family history of CaP, and pathology results. S-PLUS 2000 statistical software was utilized with p < 0.05 considered significant. Cox proportional hazards regression models with restricted cubic splines were utilized to construct the nomogram. Validation utilized bootstrapping, and the concordance index was calculated based on these predictions. Results: A total of 1,542 consecutive patients underwent primary TRUSB with a median age of 64.2 years (range 34.9-89.2 years), PSA of 5.7 ng/ml (range 0.3-3,900 ng/ml), number of cores removed of 8.0 (range 1-22) and TRUSPV of 36.4 cm3 (range 9.6-212.0 cm3). CaP was diagnosed in 561 (36.4%) patients. A nomogram was constructed incorporating age at biopsy, race, PSA, body mass index, clinical stage, TRUSPV, number of cores removed, and family history of CaP. The concordance index when validated internally was 0.802. Conclusions: We have developed and internally validated a model predicting cancer detection in men undergoing TRUSB in a contemporary series. This model may assist clinicians in risk-stratifying potential candidates for TRUSB, potentially avoiding unnecessary or low-probability TRUSB.

Original languageEnglish (US)
Pages (from-to)141-145
Number of pages5
JournalCurrent Urology
Volume6
Issue number3
DOIs
StatePublished - Jan 1 2013

Fingerprint

Nomograms
Prostate
Prostatic Neoplasms
Biopsy
Prostate-Specific Antigen
Body Mass Index
Research Ethics Committees
Proportional Hazards Models
Software
Pathology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Reproductive Medicine
  • Urology

Cite this

Diblasio, C. J., Derweesh, I. H., Maddox, M. M., Mehrazin, R., Yu, C., Malcolm, J. B., ... Kattan, M. W. (2013). Nomogram to predict prostate cancer diagnosis on primary transrectal ultrasound-guided prostate biopsy in a contemporary series. Current Urology, 6(3), 141-145. https://doi.org/10.1159/000343528

Nomogram to predict prostate cancer diagnosis on primary transrectal ultrasound-guided prostate biopsy in a contemporary series. / Diblasio, Christopher J.; Derweesh, Ithaar H.; Maddox, Michael M.; Mehrazin, Reza; Yu, Changhong; Malcolm, John B.; Aleman, Michael A.; Patterson, Anthony; Wake, Robert; Kattan, Michael W.

In: Current Urology, Vol. 6, No. 3, 01.01.2013, p. 141-145.

Research output: Contribution to journalArticle

Diblasio, CJ, Derweesh, IH, Maddox, MM, Mehrazin, R, Yu, C, Malcolm, JB, Aleman, MA, Patterson, A, Wake, R & Kattan, MW 2013, 'Nomogram to predict prostate cancer diagnosis on primary transrectal ultrasound-guided prostate biopsy in a contemporary series', Current Urology, vol. 6, no. 3, pp. 141-145. https://doi.org/10.1159/000343528
Diblasio, Christopher J. ; Derweesh, Ithaar H. ; Maddox, Michael M. ; Mehrazin, Reza ; Yu, Changhong ; Malcolm, John B. ; Aleman, Michael A. ; Patterson, Anthony ; Wake, Robert ; Kattan, Michael W. / Nomogram to predict prostate cancer diagnosis on primary transrectal ultrasound-guided prostate biopsy in a contemporary series. In: Current Urology. 2013 ; Vol. 6, No. 3. pp. 141-145.
@article{514ac275d0a8479693c6de3b65ca7a85,
title = "Nomogram to predict prostate cancer diagnosis on primary transrectal ultrasound-guided prostate biopsy in a contemporary series",
abstract = "Objective: Transrectal ultrasound-guided biopsy (TRUSB) remains the mainstay for prostate cancer (CaP) diagnosis. Numerous variables have shown associations with development of CaP. We present a nomogram that predicts the probability of detecting CaP on TRUSB. Methods: After obtaining institutional review board approval, all patients undergoing primary TRUSB for CaP detection at a single center at our institution between 2/2000 and 9/2007 were reviewed. Patients undergoing repeat biopsies were excluded, and only the first biopsy was included in the analysis. Variables included age at biopsy, race, clinical stage, prostate specific antigen (PSA), number of cores removed, TRUS prostate volume (TRUSPV), body mass index, family history of CaP, and pathology results. S-PLUS 2000 statistical software was utilized with p < 0.05 considered significant. Cox proportional hazards regression models with restricted cubic splines were utilized to construct the nomogram. Validation utilized bootstrapping, and the concordance index was calculated based on these predictions. Results: A total of 1,542 consecutive patients underwent primary TRUSB with a median age of 64.2 years (range 34.9-89.2 years), PSA of 5.7 ng/ml (range 0.3-3,900 ng/ml), number of cores removed of 8.0 (range 1-22) and TRUSPV of 36.4 cm3 (range 9.6-212.0 cm3). CaP was diagnosed in 561 (36.4{\%}) patients. A nomogram was constructed incorporating age at biopsy, race, PSA, body mass index, clinical stage, TRUSPV, number of cores removed, and family history of CaP. The concordance index when validated internally was 0.802. Conclusions: We have developed and internally validated a model predicting cancer detection in men undergoing TRUSB in a contemporary series. This model may assist clinicians in risk-stratifying potential candidates for TRUSB, potentially avoiding unnecessary or low-probability TRUSB.",
author = "Diblasio, {Christopher J.} and Derweesh, {Ithaar H.} and Maddox, {Michael M.} and Reza Mehrazin and Changhong Yu and Malcolm, {John B.} and Aleman, {Michael A.} and Anthony Patterson and Robert Wake and Kattan, {Michael W.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1159/000343528",
language = "English (US)",
volume = "6",
pages = "141--145",
journal = "Current Urology",
issn = "1661-7649",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Nomogram to predict prostate cancer diagnosis on primary transrectal ultrasound-guided prostate biopsy in a contemporary series

AU - Diblasio, Christopher J.

AU - Derweesh, Ithaar H.

AU - Maddox, Michael M.

AU - Mehrazin, Reza

AU - Yu, Changhong

AU - Malcolm, John B.

AU - Aleman, Michael A.

AU - Patterson, Anthony

AU - Wake, Robert

AU - Kattan, Michael W.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Objective: Transrectal ultrasound-guided biopsy (TRUSB) remains the mainstay for prostate cancer (CaP) diagnosis. Numerous variables have shown associations with development of CaP. We present a nomogram that predicts the probability of detecting CaP on TRUSB. Methods: After obtaining institutional review board approval, all patients undergoing primary TRUSB for CaP detection at a single center at our institution between 2/2000 and 9/2007 were reviewed. Patients undergoing repeat biopsies were excluded, and only the first biopsy was included in the analysis. Variables included age at biopsy, race, clinical stage, prostate specific antigen (PSA), number of cores removed, TRUS prostate volume (TRUSPV), body mass index, family history of CaP, and pathology results. S-PLUS 2000 statistical software was utilized with p < 0.05 considered significant. Cox proportional hazards regression models with restricted cubic splines were utilized to construct the nomogram. Validation utilized bootstrapping, and the concordance index was calculated based on these predictions. Results: A total of 1,542 consecutive patients underwent primary TRUSB with a median age of 64.2 years (range 34.9-89.2 years), PSA of 5.7 ng/ml (range 0.3-3,900 ng/ml), number of cores removed of 8.0 (range 1-22) and TRUSPV of 36.4 cm3 (range 9.6-212.0 cm3). CaP was diagnosed in 561 (36.4%) patients. A nomogram was constructed incorporating age at biopsy, race, PSA, body mass index, clinical stage, TRUSPV, number of cores removed, and family history of CaP. The concordance index when validated internally was 0.802. Conclusions: We have developed and internally validated a model predicting cancer detection in men undergoing TRUSB in a contemporary series. This model may assist clinicians in risk-stratifying potential candidates for TRUSB, potentially avoiding unnecessary or low-probability TRUSB.

AB - Objective: Transrectal ultrasound-guided biopsy (TRUSB) remains the mainstay for prostate cancer (CaP) diagnosis. Numerous variables have shown associations with development of CaP. We present a nomogram that predicts the probability of detecting CaP on TRUSB. Methods: After obtaining institutional review board approval, all patients undergoing primary TRUSB for CaP detection at a single center at our institution between 2/2000 and 9/2007 were reviewed. Patients undergoing repeat biopsies were excluded, and only the first biopsy was included in the analysis. Variables included age at biopsy, race, clinical stage, prostate specific antigen (PSA), number of cores removed, TRUS prostate volume (TRUSPV), body mass index, family history of CaP, and pathology results. S-PLUS 2000 statistical software was utilized with p < 0.05 considered significant. Cox proportional hazards regression models with restricted cubic splines were utilized to construct the nomogram. Validation utilized bootstrapping, and the concordance index was calculated based on these predictions. Results: A total of 1,542 consecutive patients underwent primary TRUSB with a median age of 64.2 years (range 34.9-89.2 years), PSA of 5.7 ng/ml (range 0.3-3,900 ng/ml), number of cores removed of 8.0 (range 1-22) and TRUSPV of 36.4 cm3 (range 9.6-212.0 cm3). CaP was diagnosed in 561 (36.4%) patients. A nomogram was constructed incorporating age at biopsy, race, PSA, body mass index, clinical stage, TRUSPV, number of cores removed, and family history of CaP. The concordance index when validated internally was 0.802. Conclusions: We have developed and internally validated a model predicting cancer detection in men undergoing TRUSB in a contemporary series. This model may assist clinicians in risk-stratifying potential candidates for TRUSB, potentially avoiding unnecessary or low-probability TRUSB.

UR - http://www.scopus.com/inward/record.url?scp=84873811666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873811666&partnerID=8YFLogxK

U2 - 10.1159/000343528

DO - 10.1159/000343528

M3 - Article

VL - 6

SP - 141

EP - 145

JO - Current Urology

JF - Current Urology

SN - 1661-7649

IS - 3

ER -